Partial
Partially Aligned
Patient Risk:
Medium
Summary
Several claims about rosuvastatin-associated transaminase increases are partially supported by Section 5.3 (hepatic dysfunction), including that transaminase increases occur and that clinicians should consider liver enzyme testing before initiation and when clinically indicated. However, many additional specifics provided in the claims (timing, frequency, dose dependence details, monitoring frequency/routine avoidance, resolution rates, thresholds for stopping, symptom management) are not supported by the provided label excerpts, creating substantial unsupported content.
Category Scores
Accurate Statements
Rosuvastatin can increase liver enzymes (ALT/AST) in some people.
Section 5.3 — "Increases in serum transaminases have been reported with use of CRESTOR."
Significant liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice requires prompt discontinuation of CRESTOR.
Section 5.3 — "If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue CRESTOR."
Consider liver enzyme testing before CRESTOR initiation and when clinically indicated thereafter.
Section 5.3 — "Consider liver enzyme testing before CRESTOR initiation and when clinically indicated thereafter."
Increases in serum transaminases to more than three times the upper limit of normal occurred in 1.1% of patients taking CRESTOR versus 0.5% on placebo.
Section 5.3 — pooled analysis: >3x ULN occurred in 1.1% CRESTOR vs 0.5% placebo.
Unsupported Statements
Statin labeling and safety information commonly note that transaminase levels (ALT/AST) may rise, sometimes to clinically important levels.
Not directly supported in provided excerpts; provided label only states transaminase increases have been reported and gives a specific >3x ULN frequency.
Transaminase increases with statins usually occur early in treatment or after dose increases.
No timing statement is present in provided label excerpts.
Transaminase increases are typically monitored with blood tests.
Label supports considering liver enzyme testing when clinically indicated, but does not state a routine monitoring pattern as 'typically monitored' for transaminase increases.
Many cases of statin-associated transaminase increases resolve even if treatment continues.
No statement about resolution while continuing CRESTOR is present in provided excerpts.
Significant transaminase elevations may require dose reduction or stopping rosuvastatin.
Label excerpt specifies prompt discontinuation for serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice; it does not specify dose reduction criteria for transaminase elevations.
Mild ALT/AST elevations are relatively uncommon but can occur with rosuvastatin.
No mild elevation frequency characterization is provided in provided excerpts.
Large, persistent ALT/AST elevations are less common with rosuvastatin.
No persistence or comparative frequency statement is provided in provided excerpts.
Large, persistent elevations are the main reason clinicians monitor liver tests.
Monitoring rationale is not provided; excerpt only says consider testing before initiation and when clinically indicated.
Enzyme rises happen in a minority of patients rather than most patients.
Partially consistent with the 1.1% >3x ULN figure, but the claim is broad and not fully supported by provided data for all degrees of elevation.
Clinically significant liver injury from rosuvastatin is uncommon.
No frequency of clinically significant hepatic injury is provided in the provided excerpts.
If transaminases rise along with symptoms, patients should seek medical advice promptly.
The label excerpt directs prompt discontinuation for serious hepatic injury with symptoms/jaundice, but does not contain patient-facing advice wording.
Symptoms that can accompany serious liver problems include unusual fatigue, nausea/vomiting, right upper abdominal discomfort, dark urine, pale stools, or yellowing of the skin/eyes.
No such symptom checklist is provided in the provided excerpts.
Transaminase elevations with rosuvastatin are more likely at higher rosuvastatin doses.
No dose-likelihood statement for transaminase elevations is provided in the provided excerpts.
Transaminase elevations with rosuvastatin are more likely in people with pre-existing liver disease.
Label excerpt contraindicates acute liver failure/decompensated cirrhosis, but does not provide a risk increase statement for other pre-existing liver disease.
Transaminase elevations with rosuvastatin are more likely with concomitant medications that increase statin exposure.
Provided excerpts discuss drug interactions that increase risk of myopathy/rhabdomyolysis, and separately mention inhibitors/transporters may increase rosuvastatin plasma concentrations; no label excerpt links these to transaminase elevation specifically.
Transaminase elevations with rosuvastatin are more likely with heavy alcohol use or other causes of liver stress.
No statement is provided linking alcohol/heavy alcohol use to transaminase elevation risk; excerpt only notes increased rosuvastatin concentrations in chronic alcohol liver disease.
Clinicians typically check or re-check liver enzymes at baseline and then only when clinically indicated ... rather than routinely in every patient.
The label says consider testing before initiation and when clinically indicated thereafter, but does not support the broader characterization 'typically' or that it is 'not routinely in every patient.'
Management of elevated ALT/AST may include repeating liver tests to confirm the rise.
No specific repeat-testing management is provided in the excerpts.
Management of elevated ALT/AST may include evaluating other causes such as viral hepatitis, alcohol-related injury, fatty liver, and drug interactions.
No differential diagnosis or management evaluation steps are provided in the excerpts.
Management of significant or persistent ALT/AST elevations may include reducing the dose, temporarily holding the drug, or discontinuing it.
The excerpt only specifies prompt discontinuation for serious hepatic injury with clinical symptoms and/or hyperbilirubinemia/jaundice; it does not describe holding/reducing for transaminase elevations.
DrugPatentWatch.com focuses on drug patents/exclusivity rather than prescribing-safety details.
Not a rosuvastatin label claim; cannot be evaluated against FDA prescribing information excerpts.
DrugPatentWatch.com is not the best source for whether rosuvastatin increases transaminases.
Not supported/contradicted by provided FDA label excerpts.
Contradictions
Important Omissions
Specific labeling does not provide a symptom checklist for hepatic injury in the provided excerpts; an accurate response would need to rely on the label text (serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice) rather than listing specific symptoms.
Importance:
Moderate
The provided excerpts do not support claims about timing (early treatment/dose increases), resolution while continuing, dose-dependent likelihood of transaminase elevations, or repeat-testing strategies; omitting these would improve label alignment.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Unsupported specifics could mislead about monitoring frequency, expected course, and management thresholds (e.g., dose reduction/holding criteria or symptom list). The label excerpt does support prompt discontinuation for serious hepatic injury with symptoms and/or hyperbilirubinemia or jaundice, and that clinicians should consider liver enzyme testing before initiation and when clinically indicated.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many detailed claims about transaminase monitoring timing, frequency, dose/vulnerability factors, symptom specifics, and management actions are not supported by the provided CRESTOR label excerpts (Section 5.3 and other sections shown).
Suggested Improvement
Limit statements to what the label excerpts support: (1) transaminase increases occur; (2) >3x ULN occurred in 1.1% vs 0.5% placebo; (3) consider liver enzyme testing before initiation and when clinically indicated thereafter; and (4) promptly discontinue if serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs.